NCI Working Group on Biochemically Recurrent Prostate Cancer: Trial Design Guidance for a PSMA Era
The NCI convened experts to provide clinical-trial design recommendations for biochemically recurrent prostate cancer in the era of PSMA PET, defining PSMA+BCR, high-risk criteria, imaging and data standards, endpoint suggestions, and a push toward deintensification to limit toxicity.
